CJM-112
Based on 1 Customer Validation
CJM112 is a fully human IgG1/κ monoclonal antibody inhibitor targeting IL-17A, which binds to IL-17A and the IL-17AF heterodimer with high affinity, with KD values of 5.7 pM and <11 pM, respectively. CJM-112 exerts anti-inflammatory effects by neutralizing IL-17A, and reduces the Psoriasis Area and Severity Index in a time- and dose-dependent manner. CJM-112 also exhibits anti-inflammatory activity and improves disease severity in studies of hidradenitis suppurativa. CJM-112 shows favorable biosafety and tolerability. CJM-112 can be used in studies related to psoriasis and hidradenitis suppurativa.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.65%
- 분자량:144.707 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
|
IL-17A 5.7 pM (Kd) |
IL-17AF <11 pM (Kd) |
CJM-112 binds to human IL-17A and IL-17AF with high affinity (with KD values of 5.7 pM and <11 pM, respectively), and neutralizes cytokine production induced by IL-17A and IL-17AF in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized IL17A-mFc can bind CJM-112. The EC50 for this effect is 63.3 ng/mL.
Chemical Information
-
Appearance Liquid
-
분자량 144.707 kDa
-
Color Colorless to light yellow
-
SMILES
[CJM-112]
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kaul M, et al. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021 May;35(5):1143-1151. [Content Brief]
[2]. Kimball AB, et al. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study. Experimental dermatology. 2022 Oct;31(10):1522-1532. [Content Brief]
[3]. Thiboutot DM, et al. Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne. The Journal of dermatological treatment. 2023 Dec;34(1):2138691. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CJM-112 Related Classifications
HY-P991261 Related Classifications
Powered by Bioz